For Healthcare Professionals

Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101

clipboard-pencil

About the study

Subjects are enrolled in this study following completion or early discontinuation from a Poseida sponsored or supported study of P-BCMA-101 T cells and will be followed for a total of 15 years post treatment from the last P-BCMA-101 treatment. Subjects will be monitored for safety and efficacy to assess the risk of delayed adverse events (AEs) and assess long-term efficacy, and PK and quantification of P-BCMA-101 T cells. Rimiducid may be administered as indicated.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

  1. Subjects who have received P-BCMA-101 and completed or discontinued early from a Poseida sponsored treatment protocol.
  2. Subject has provided informed consent.

EXCLUSION CRITERIA

  1. None
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.

Study’s details


Contition

Multiple Myeloma

Age

18+

Phase

Phase 1

Participants needed

100

Est. Completion Date

Nov 2032

Treatment type

Interventional


Sponsor

Poseida Therapeutics, Inc.

ClinicalTrials.gov identifier

NCT03741127

Study number

P-BCMA-101-002

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.